| Autor: |
Ahuja, Manisha, Dorr, Anthony, Bode, Eniola, Boulton, Anne P. R., Buckland, Matthew, Chee, Samuel, Dalley, Claire, Denman, Sarah, Ekbote, Anjali, Elkhalifa, Shuayb, El‐Shanawany, Tariq, Eren, Efrem, Herwadkar, Archana, Garcez, Tomaz, Ghanta, Harichandana, Grammatikos, Alexandros, Grigoriadou, Sofia, Jain, Rashmi, Lorenzo, Lorena, Manson, Ania |
| Předmět: |
|
| Zdroj: |
Allergy; May2023, Vol. 78 Issue 5, p1380-1383, 4p |
| Abstrakt: |
TREATMENT FAILURE Twelve (22%) patients in the survey stopped treatment before the 6-month analysis compared to 3% reported in the trials.[[1], [3]] Nine of these patients stopped treatment due to adverse side effects. This included the validated tool for patient-reported outcome measures, the Angioedema Control Test (AECT).[6] BASELINE PROPHYLAXIS Most patients (32, 59.3%) were receiving prophylaxis prior to starting berotralstat. To the Editor, Berotralstat is an oral plasma kallikrein inhibitor, used for routine prevention of attacks of hereditary angioedema (HAE) Type 1 and Type 2. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text